THERAPY DOSSIER · th-c63ef4616b29

Human urinary kallidinogenase

Biologic · No mechanism-of-action record in ChEMBL. ChEMBL molecule_type Enzyme; ATC C04AF01 (peripheral vasodilator, enzyme). Pharmacologically a tissue kallikrein that releases kinins and acts via the bradykinin B2 receptor, but that mechanism is not asserted by ChEMBL.

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: No mechanism-of-action record in ChEMBL. ChEMBL molecule_type Enzyme; ATC C04AF01 (peripheral vasodilator, enzyme). Pharmacologically a tissue kallikrein that releases kinins and acts via the bradykinin B2 receptor, but that mechanism is not asserted by ChEMBL.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL2109067 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Carnaculin; Glandular kallikrein porcine; Kallidinogenase (human urine); Padutin; Kallikrein, pancreatic porcine
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02562183 ↗PHASE4unknown

The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

Cerebral Infarction

Enrolment: 2186 · Results not recorded

NCT03431909 ↗PHASE4completed

Evaluation of Human Urinary Kallidinogenase in Acute Stroke Patients: Magnetic Resonance Spectrum and CT Perfusion

Acute Ischemic Stroke

Enrolment: 80 · Results not recorded

NCT04102956 ↗PHASE4completed

Human Urinary Kallidinogenase Improves Short Term Motor Functional Outcome by Reducing Corticospinal Tract Damage in Acute Ischemic Stroke

Stroke, Acute

Enrolment: 80 · Results not recorded

NCT02259738 ↗PHASE2completed

Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase

Cerebral Infarction

Enrolment: 120 · Results not recorded

NCT06380699 ↗PHASE1completed

Phase I Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection (vs Human Urinary Kallidinogenase) in Chinese Healthy Subjects

Acute Ischemic Stroke

Enrolment: 56 · Results not recorded

NCT06132880 ↗NAnot yet recruiting

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

Acute Ischemic Stroke

Enrolment: 540 · Results not recorded

NCT07483281 ↗NAnot yet recruiting

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in Acute Ischemic Stroke

Acute Ischemic Stroke

Enrolment: 220 · Results not recorded

NCT06848894 ↗NArecruiting

Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

Acute Ischemic Stroke

Enrolment: 1204 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29510144 ↗2018Reported benefit

Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMaleIntra-arterial

Model: Permanent middle cerebral artery occlusion in rats

Intra-arterial human urinary kallidinogenase improved neurological deficit scores, reduced infarct area, neurodegeneration and pro-inflammatory cytokines, raised IL-10 and reduced apoptosis markers, with the benefit abolished by PI3K inhibition.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…